The Impact of China's Zero Markup Drug Policy on Hospitalization Expenses for Inpatients in Tertiary Public Hospitals: Evidence Based on Quantile Difference-in-Difference Models

被引:9
|
作者
Ni, Ziling [1 ]
Jia, Jie [1 ]
Cui, Lu [1 ]
Zhou, Siyu [1 ]
Wang, Xiaohe [1 ]
机构
[1] Hangzhou Normal Univ, Sch Publ Hlth, Dept Hlth Serv Management, Hangzhou 311100, Peoples R China
基金
中国国家自然科学基金;
关键词
Zero Markup Drug Policy; hospitalization expenses; QDID; tertiary hospitals; HEALTH-CARE UTILIZATION; INCENTIVES; EXPENDITURE; GOVERNMENT; REGRESSION; COSTS;
D O I
10.3390/healthcare9070908
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: The aim of this study was to determine the impact of the Zero Markup drug (ZMD) policy on hospitalization expenses for inpatients in tertiary Chinese hospitals. Methods: Using the administrative data from hospital electronic health records (EHRs) between 2015 and 2017, we implemented the quantile difference-in-differences (QDID) estimators to evaluate the impact of the ZMD policy on hospitalization expenses while controlling for patient-level and hospital-level characteristics. Results: According to the QDID models, the introduction of ZMD policy significantly induced lower drug costs for all inpatients especially at the 50th (-USD 507.84 (SE = USD 90.91), 75th (-USD 844.77 (SE = USD 149.70), and 90th (-USD 1400.00 (SE = USD 209.97)) percentiles of the overall distributions. However, the total hospitalization, diagnostic, treatment, material and services expenses for inpatients were significantly higher for the treated group than the control group. This tendency was more pronounced for inpatients in tertiary hospitals with lower expenses (in the 10th, 25th and 50th percentiles). Conclusion: The implementation of ZMD policy alone may not be enough to change the medical service providers' profit-driven behavior. The targeted supervision of hospital costs by the Chinese health administration department should be strengthened to avoid unreasonable hospital charges.
引用
收藏
页数:11
相关论文
共 4 条
  • [1] Impact of Medical-Pharmaceutical Separation Reform on Hospitalization Expenditure in Tertiary Public Hospitals: Difference-in-Difference Analysis Based on Panel Data from Beijing
    Wang, Wenjuan
    Liang, Juanjuan
    Fan, Rong
    Cai, Yuanqing
    Yin, Baisong
    Hu, Yangyi
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2024, 17 : 1263 - 1276
  • [2] Differential effect of China's Zero Markup Drug Policy on provider-induced demand in secondary and tertiary hospitals
    Zhang, Xiaoxi
    Zimmerman, Armand
    Lai, Hongyu
    Zhang, Yanyan
    Tang, Zhongyi
    Tang, Shenglan
    Ogbuoji, Osondu
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [3] Can zero-markup policy for drug sales in public hospitals resolve the problem of 'seeing a doctor is too expensive' in China? A ease study of four municipal general tertiary hospitals at H City in Z Province
    He, Ziying
    Zhou, Jinying
    JOURNAL OF CHINESE GOVERNANCE, 2017, 2 (03) : 329 - 342
  • [4] Impact of an ICU bed capacity optimisation method on the average length of stay and average cost of hospitalisation following implementation of China's open policy with respect to COVID-19: a difference-in-differences analysis based on information management system data from a tertiary hospital in southwest China
    Zheng, Qingyan
    Zeng, Zhongyi
    Tang, Xiumei
    Ma, Li
    BMJ OPEN, 2024, 14 (04):